statement
Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
D2T RA 임상 성공에 따라 위험 할인을 기존 50%에서 40%로 축소하며 IMVT-1402의 가치 재평가
Related claims
Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statementDevelopers removed version 4 transactions, the only means of spending those coins, to eliminate old and complex verification code and denial-of-service (DoS) risk.AIXBT · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementThe trade has a 3:1 risk-reward ratio.derstandardat · statement